KIYATEC
Greenville
About KIYATEC
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co-culture, and is a single-use disposable. 3DKUBE cell-based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $48.9M
- Last round: Corporate Round (Nov 2025)
- Website: kiyatec.com
- Phone: 864-502-2013
Industries & Categories
Biotechnology, Health Diagnostics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/kiyatec-95237 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.